Stage 1: Bromantane and 9-Me-BC
Bromantane acts as a dopamine synthesis enhancer by increasing the expression of tyrosine hydroxylase and aromatic L-amino acid decarboxylase, enzymes responsible for dopamine synthesis. It also inhibits dopamine reuptake, leading to increased dopamine availability in the synaptic cleft.
9-Me-BC has been shown to promote the regeneration of dopaminergic neurons, potentially increasing the density and functionality of dopamine receptors. This effect is believed to be due to its ability to inhibit the enzyme monoamine oxidase B (MAO-B) and its antioxidant properties, which protect dopaminergic neurons from oxidative stress.
Stage 2: Cyclazodone
Cyclazodone is a stimulant that primarily acts on the dopaminergic and noradrenergic systems by inhibiting the reuptake of dopamine and norepinephrine. This increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling and leading to improved focus, attention, and motivation.
Interplay between stages:
In the first stage, the combination of Bromantane and 9-Me-BC increases dopamine synthesis and receptor density, creating a foundation for enhanced dopamine signaling. When you transition to the second stage and introduce cyclazodone, the increased availability of dopamine and norepinephrine, coupled with the enhanced receptor density from the first stage, may result in more effective neurotransmission and greater cognitive effects.
When cycling back to the first stage, the continued use of Bromantane and 9-Me-BC may help maintain the increased dopamine synthesis and receptor density achieved during the previous cycle. This could potentially sustain or further enhance the benefits derived from cyclazodone in the second stage.
This cycling approach, in theory, may lead to a synergistic effect, where the increased dopamine synthesis and receptor density from Stage 1 potentiate the effects of cyclazodone in Stage 2, and the subsequent reintroduction of Stage 1 maintains or enhances these effects.
Methylene blue and 9-Me-BC may have complementary effects on cognitive function and mood. Methylene blue is an MAOI that can increase dopamine and norepinephrine levels, while 9-Me-BC promotes the regeneration of dopaminergic neurons and improves cognitive function. However, combining these two substances could increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by the accumulation of serotonin in the brain.
Moreover, 9-Me-BC is photosensitive and can be activated by light, which may affect its stability and effectiveness. Methylene blue, on the other hand, is a potent dye that absorbs light in the blue spectrum, potentially affecting the photoresponsiveness of 9-Me-BC.